Condition: Coronary Artery Disease · Acute Kidney Injury · Contrast-Induced Acute Kidney Injury · Sponsor: Collegium Medicum w Bydgoszczy
All consecutive patients hospitalized from 01.01.2020 to 30.09.2025 who underwent coronary angiography or PCI will be eligible for inclusion. The final analysis will be limited to individuals in whom the volume of ICM administered during the index procedure was between 50 and 500 mL and for whom both pre- and post-procedure serum creatinine measurements were available. The primary objective of the study is the effect of short-term and long-term SGLT2i therapy on the occurrence of CI-AKI in patients undergoing diagnostic or therapeutic procedures with ICM.
This description comes directly from the study's public registry record.
Piotr Niezgoda, MD, PhD · +48525854023 · piotr.niezgoda1986@gmail.com
Always discuss trial participation with your own doctor first.
| Collegium Medicum w Bydgoszczy | Bydgoszcz, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07231939